tbuckley/cabot-search huggingface dataset:
Reducing administrative burden through the use of IT tools.
Authors: Andrew Rothacker, Katherine Glass
Journal: Journal of Clinical Oncology (2019)

300 Background: With the increasing cost of healthcare, providers have been tasked with increasing efficiencies. While the Electronic Medical Record (EMR) is a great tool for managing the patient at the time of their appointment, it can be difficult to utilize that information outside of and prior to the appointment. We recognized the need for better reporting to enable the end users to spend less time in front of a screen and more time with their patients. The need for better, more efficient data was evident. Simple data extracts from the EMR were not working. Methods: The operations analysts attended weekly huddles, shadowed clinicians, and immersed themselves in the data to better understand what is required from the reports. Multiple patient databases were created, along with dashboards, using a visual software package to display patient information. Information is then filtered into the dashboard for reporting, examples include: the patient’s appointments, treatment length, treatment location, and any other pertinent information that is needed. The reports are then automated to provide users a report with a specific snapshot of the patients coming to the clinic the following day/week. End users are then able to take the reports provided to them automatically and plan their time accordingly. Results: The reports are used daily/weekly (depending on the need of the report) by clinical and non-clinical teams. By leveraging appointment data from the back end of the EMR and the visual software package, end users no longer need to spend time combing through the EMR to identify future appointments. Information is tailored to their specific needs, which may be different from a clinical team to a non-clinical team. While it is difficult to quantify the exact value each report provides, one specific example for the Art &amp; Music Therapy team is saving end users an estimated 4 hours per day, extrapolating out to 1,040 hours per year and freeing them up to provide better service to their patients. Conclusions: Combining appointment data and data visualization and automation tools allows teams to review the necessary information more efficiently. By reducing the manual burden of searching through the EMR, end users are able to free up their time and spend more time with the patient.
Target engagement and intracellular delivery of mono- and bivalent LDL receptor-binding peptide-cargo conjugates: Implications for the rational design of new targeted drug therapies
Authors: K. Varini, P. Lécorché, R. Sonnette, F. Gassiot, B. Broc, M. Godard, M. David, A. Faucon, K. Abouzid, G. Ferracci, J. Temsamani, M. Khrestchatisky, G. Jacquot
Journal: Journal of Controlled Release (2019)
Liposome-Encapsulated Doxorubicin Is Highly Active in Patients with B- as Well as T/NK-Cell Lymphomas and Cardiac Comorbidity or Older Age
Authors: Cathri n C Skrabs, Alexander Hauswirth, Karin Eigenberger, Christine Einberger, Markus Raderer, Wolfgang R Sperr, Paul Knoebl, Leonhard Muellauer, Martin Uffmann, Karin Dieckmann, Alexander Gaiger, Ulrich Jaeger
Journal: Blood (2008)
Development and testing of patient-reported outcome performance measures (PRO-PMs) for oncology practice.
Authors: Angela M. Stover, Ben Urick, Allison Mary Deal, Jennifer Jansen, Sydney Henson, Robert S. Miller, Tenbroeck Smith, Sarah Hudson Scholle, Anne C. Chiang, Charles S. Cleeland, Yehuda Ethan Deutsch, Dylan M. Zylla, Collette Pitzen, Claire Frances Snyder, Kristen K. McNiff, Monika K. Krzyzanowska, Patricia Spears, Mary Lou Smith, Cindy Geoghegan, Ethan M. Basch
Journal: Journal of Clinical Oncology (2019)

173 Background: Symptom management is a cornerstone of quality oncology practice. ASCO established a Working Group to develop patient-reported outcome performance measures (PRO-PMs) for assessing symptom management. We describe multi-center testing funded by PCORI. Methods: Multi-stakeholder consensus and literature review identified 11 symptoms for testing as potential PRO-PMs. For these symptoms, questions from the NCI’s PRO-CTCAE tool were administered at 6 US academic and community oncology practices. Patients across cancer types completed questions electronically on days 5-15 of chemotherapy cycles. PRO-CTCAE mapped scores were dichotomized to delineate clinically meaningful thresholds (0-1 vs ≥2), and rates were tabulated between practices. Symptoms were selected to become PRO-PMs if clinically actionable and with prevalence ≥20%; between-practice variation was evaluated using χ 2 . Twelve candidate sociodemographic and clinical risk adjustment (RA) variables were evaluated via Akaike information criterion testing. Risk-adjusted PRO-PM rates were calculated using observed:expected ratios via generalized linear mixed modeling. Results: Among 653 enrolled patients, 607 (93%) completed questionnaires. Four of 11 symptoms met criteria for PRO-PM development: nausea, constipation, insomnia, pain. Four RA variables met inclusion criteria: age, gender, cancer type, insurance type. The Table shows raw and risk-adjusted rates of symptom burden (scores ≥2) for each PRO-PM across practices. Risk-adjustment yielded a modest impact on scores. Conclusions: Oncology PRO-PMs have been developed to quantify the burden of actionable symptoms at the practice level. Collection from patients is feasible. Further refinement is underway prior to submission for endorsement by the National Quality Forum. [Table: see text]
Molecular Status Evaluation in a Standardized Laboratory in a Cohort of Patients with Chronic Myeloid Leukemia At the Instituto Mexicano Del Seguro Social (IMSS)
Authors: Luis A Meillón, Carolina Sandoval-Sanchez, Nancy Delgado-Lopez, Manuel Ayala, Yolanda Lugo, Maria Mora, Noe Diaz-Robles, Patricia Oropeza, Angelica Romo, Kevin Nacho-Vargas
Journal: Blood (2012)
The Depth of Renal Response Strongly Predicts Overall Surival in Patients with AL Amyloidosis
Authors: Siobhan V Glavey, Angela Dispenzieri, Morie A Gertz, Shaji Kumar, Martha Q Lacy, Francis K Buadi, S. Vincent Rajkumar, Suzanne R Hayman, John A Lust, Stephen J. Russell, Steven R Zeldenrust, David Dingli, Rob L Hall, Nelson Leung
Journal: Blood (2011)
Universal hepatitis B screening in a high risk community.
Authors: Ivy Abraham, Jane Mccullough, Janet Golick, Kasandra Cadman, Gay Cirignani, Megan Sta Maria, Vera Maynard, Lupe Nelson, Susan Nishimura, Elizabeth Oremovich, Lydia Palma, LeeAnn Valero, Maria Walker, Stacey Zubel, Sandra Cuellar, Wadih Chacra, Neeta K. Venepalli
Journal: Journal of Clinical Oncology (2019)

244 Background: 2015 ASCO guidelines for Hepatitis B (HBV) screening in patients (pts) receiving chemotherapy recommend a risk-adaptive strategy considering patient and treatment-specific factors. The University of Illinois Cancer Center (UICC) is an academic center with largely underserved, minority and socioeconomically disadvantaged pts. UICC implemented a universal HBV screening policy in 2016. We aimed to increase HBV screening from 60% to 95% over 18 months. Methods: A multidisciplinary team of oncologists, hepatologists, fellows, nurses and pharmacists created an ideal process map for universal HBV screening in all pts starting chemotherapy outlining screening parameters, laboratory tests required and follow-up for positive screens. Four Plan-Do-Study-Act cycles were tested. Interim analysis was done targeting specific providers for additional education. Results of screening were analyzed by chart review. Results: A total of 589 treatment-naive pts were screened for HBV between Aug 2017 and Feb 2019. Educational sessions were held for nurses, pharmacists and fellows to review ideal process maps between Jan and March 2018. 0% of pts had insurance denials for HBV screening coverage. Screening rates improved from 65% in Aug 2017 to 100% in Feb 2019. Positive HBV screen rate was 3% (N = 18) and all were new diagnoses. 61% (N = 11) of positive screens had no risk factors for HBV exposure and would not have met risk adaptive criteria for screening. 27% (N = 3) of positive screens without prior risk factors were initiated on prophylactic ART. 50% (N = 9) of all new HBV diagnoses initiated prophylactic ART to prevent reactivation, while 50% received active surveillance on chemotherapy. 0% of pts on active surveillance developed reactivation. Conclusions: Implementing and sustaining a universal HBV screening program was feasible and effective in identifying pts at risk for reactivation in a high risk population. 61% of positive screens lacked traditional risk factors. Risk-adaptive screening may miss cases in diverse populations where HBV is not endemic, precluding appropriate management. Further evaluation will include expanding screening to inpatient chemotherapy starts and cost-benefit analysis of universal screening in this unique population.
The Renin-Angiotensin Axis Regulates the Development of a Yolk Sac-Like Hemangioblastic Progenitor of Primitive and Definitive Hematopoiesis from Human Pluripotent Stem Cells.
Authors: Elias T. Zambidis, Tea Soon Park, Ada Tam, Michal Levine, Bruno Peault
Journal: Blood (2007)
Cells Lacking the PolQ Polymerase Are Moderately Sensitive to Ionizing Radiation and the Oxidant Induced Toxicity of Paraquat and Bleomycin.
Authors: Julie P. Goff, Michael W. Epperly, Donna S. Shields, Tracy Smith, Mineaki Seki, Hong Wang, John P. Wittschieben, Richard D. Wood, Stephen D. Dertinger, Dorothea K. Torous, Joel S. Greenberger
Journal: Blood (2007)
A nutritional memory effect counteracts the benefits of dietary restriction in old mice
Authors: Oliver Hahn, Lisa F. Drews, An Nguyen, Takashi Tatsuta, Lisonia Gkioni, Oliver Hendrich, Qifeng Zhang, Thomas Langer, Scott Pletcher, Michael J. O. Wakelam, Andreas Beyer, Sebastian Grönke, Linda Partridge
Journal: Nature Metabolism (2019)
Evidence for Bisphenol B Endocrine Properties: Scientific and Regulatory Perspectives
Authors: Hélène Serra, Claire Beausoleil, René Habert, Christophe Minier, Nicole Picard-Hagen, Cécile Michel
Journal: Environmental Health Perspectives (2019)

à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
Using the 9-Item Patient Health Questionnaire to Screen for and Monitor Depression
Authors: Mark Zimmerman
Journal: JAMA (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Retraction: The Raf Inhibitor BAY 43-9006 (Sorafenib) Induces Caspase-Independent Apoptosis in Melanoma Cells
Authors: David J. Panka, Wei Wang, Michael B. Atkins, James W. Mier
Journal: Cancer Research (2019)

[This article][1] ([1][2]) has been retracted at the request of the authors. Following an institutional review by Harvard Medical School and the Beth Israel Deaconess Medical Center, the primary affiliation for several of the authors, it was determined that some of the Western blot data depicted in
The effectiveness of two silicone dressings for sacral and heel pressure ulcer prevention compared with no dressings in high‐risk intensive care unit patients: a randomized controlled parallel‐group trial
Authors: E. Hahnel, M. El Genedy, T. Tomova‐Simitchieva, A. Hauß, A. Stroux, A. Lechner, C. Richter, M. Akdeniz, U. Blume‐Peytavi, N. Löber, J. Kottner
Journal: British Journal of Dermatology (2019)

There is a high incidence of pressure ulcers in high‐risk settings such as intensive care. There is emerging evidence that the application of dressings to pressure ulcer predilection areas (sacrum and heels) improves prevention strategies. To determine whether preventive dressings, applied to the sacrum and heels of high‐risk patients in intensive care units, in addition to standard prevention, reduces the incidence of pressure ulcers. Between June 2015 and July 2018, a randomized, controlled, two‐arm, superiority pragmatic study was performed with a concealed 1 : 1 allocation to the intervention and control group. Patients assigned to the intervention group had dressings applied to the sacrum and heels. In total, 7575 patients were screened for eligibility and 475 patients were included and allocated to both groups. Finally, 212 patients in the intervention group and 210 in the control group were analysed. The mean age was 63·5 years and the majority of patients were male (65·4%). The cumulative pressure ulcer incidence category II and above was 2·8% in the intervention, and 10·5% in the control group (P = 0·001). Compared with the control group, the relative risk in the intervention group was 0·26 [95% confidence interval (CI) 0·11–0·62] and the absolute risk reduction was 0·08 (95% CI 0·03–0·13). The results indicate that the application of dressings, in addition to standard prevention, in high‐risk intensive care unit patients is effective in preventing pressure ulcers at the heels and sacrum. What's already known about this topic? Pressure ulcers are severe soft tissue injuries and wounds, which occur worldwide in all healthcare settings. Despite preventive interventions, pressure ulcers still develop. There is emerging evidence that dressings help to prevent pressure ulcers. What does this study add? The incidence of pressure ulcers in intensive care units among high‐risk patients remains high. The application of dressings to the sacrum and heels, in addition to standard preventive measures, reduces the relative and absolute risks for the development of pressure ulcers. The application of preventive dressings at the heels and sacrum seems to be feasible in intensive care settings. Linked Comment:Nixon. Br J Dermatol 2020; 183:200–201.
Distress screening in cancer survivorship.
Authors: Julia P. Brockway-Marchello, Haley Hines Theroux, Sophia Tsesmelis Piccolino, Qiuchen Yang, Cardinale B. Smith
Journal: Journal of Clinical Oncology (2019)

138 Background: Cancer survivors have varied physical, psychosocial, emotional and financial needs that may differ from needs of active cancer treatment patients. Distress screening identifies and monitors the needs of patients and is mandated for certain accreditations. There is a paucity of data on the application of distress screening among survivors. We used a validated distress screening tool to conduct a needs assessment of cancer survivors in solid oncology. Methods: The Cancer Support Source Distress Screening tool is an 18-item survey given on the 2nd and every 3-month clinic visit to assess depression and distress. The first analysis, merged patient data (patients completing ≥ 2) with cancer registry to identify solid cancer survivors from July 2015 to October 2018. A descriptive analysis of these patients was performed. The second analysis was cross-sectional with a larger data set of all solid tumor patients completing a survey at any time pre, during, or post treatment. We compared distress and depression scores using analysis of variance. A bivariate and multivariate analysis evaluating change in depression and distress scores over time is ongoing. Results: In analysis one, 92 patients were identified. Depression scores improved for most cancer types; distress scores improved for all cancers. Emotional, communication, provider relationship, system of care, body image and social support were associated with significant changes in survivorship concern. In the expanded dataset, 908 patients were identified. The distribution of depression and distress scores are shown in the table. There was a significant decrease for depression scores (p&lt;.001) and distress scores (p&lt;.001). Multivariate analysis to evaluate change in depression and distress scores across the survivorship trajectory is ongoing. Conclusions: A distress screening survey may be a useful tool in assessing the unmet needs of cancer survivors. Identifying prevalent domains of survivorship issues can highlight areas of greatest perceived need and can guide quality improvement initiatives within a cancer program. [Table: see text]
Abstract 266: Sex Differences in Anthracycline-Induced Cardiotoxicity in Young Mice
Authors: Marianne Grant, Beshay Zordoky
Journal: Circulation Research (2019)

Introduction: The role of sex as a risk factor for Anthracycline-Induced Cardiotoxicity (AIC) is not well defined. In pediatric cancer patients, most studies report that female sex is a significant risk factor for AIC. Conversely, in adult preclinical rodent studies, there is clear evidence that female sex is protective against AIC, with a possible protective role of female sex hormones and/or a detrimental role of male sex hormones. However, sex differences in AIC have not been reported in young experimental animals. Therefore, the current work aims to characterize sex differences in AIC in young male and female mice. Methods: Five-week old male and female C57Bl/6 mice were injected with doxorubicin (DOX) 4 mg/kg/week IP for 3 to 6 weeks. After a 5-week recovery period, a cohort of control and DOX-treated mice were administered daily IP injections of isoproterenol (10 mg/kg) for 14 days to determine the effect of catecholamine stress on cardiac function and morphometry in DOX-exposed mice. Another cohort of gonadectomized and sham-operated male and female mice were injected with DOX 4 mg/kg/week for 5 weeks. Cardiac function and morphometry were measured by trans-thoracic echocardiography 5 weeks after the last DOX injection and after 14 days of isoproterenol injections. Results: In male mice only, DOX 4 mg/kg/week for 3 to 5 weeks caused cardiac atrophy without decline in cardiac function, whereas DOX administration for 6 weeks caused cardiac atrophy and dysfunction. Female mice were protected from both cardiac atrophy and dysfunction at the 3-6 weeks regimens. Isoproterenol caused cardiac dysfunction in male and female control and DOX-treated mice. Male, but not female, DOX-exposed mice failed to develop cardiac hypertrophy when challenged by isoproterenol. Intriguingly, castration of male mice exacerbated DOX-induced cardiac atrophy, while ovariectomy had no significant effect. Conclusion: In contrast to most clinical studies, young female mice are protected against DOX-induced cardiac atrophy and dysfunction. Juvenile exposure to DOX modulated the cardiac response to isoproterenol in a sex-dependent manner. Deprivation of sex hormones by gonadectomy did not reverse this sexual dimorphism, suggesting that other mechanisms are implicated.
A Randomized, Double-Blind, Adaptive Phase 2 Multi-Center Study of Prasugrel Compared to Placebo in Adults with Sickle Cell Disease
Authors: Ted Wun, Denis Soulieres, Lakshmanan Krishnamurti, Abdullah Kutlar, Kenneth Ataga, Chunmei Zhou, Lori E. Heath, Chuke E. Nwachuku, Joseph A. Jakubowski, Kenneth J. Winters, Jeffrey S. Riesmeyer
Journal: Blood (2011)
Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG
Authors: Jamie N. Anastas, Barry M. Zee, Jay H. Kalin, Mirhee Kim, Robyn Guo, Sanda Alexandrescu, Mario Andres Blanco, Stefanie Giera, Shawn M. Gillespie, Jayanta Das, Muzhou Wu, Sarah Nocco, Dennis M. Bonal, Quang-De Nguyen, Mario L. Suva, Bradley E. Bernstein, Rhoda Alani, Todd R. Golub, Philip A. Cole, Mariella G. Filbin, Yang Shi
Journal: Cancer Cell (2019)
Redefining functional status as a key cancer outcome: Patient-led measure conceptualization and development.
Authors: Kristen K. McNiff, Shelley Fuld Nasso
Journal: Journal of Clinical Oncology (2019)

218 Background: Multiple national quality committees have identified PRO-PMs as priority for cancer measure development. Further, measurement of ‘return to functional status’ (RFS) has been prioritized. Finally, stakeholders have called for more patient-centric approaches to measure development. Accordingly, NCCS initiated a project funded by AIR to lead conceptual development and pre-testing specification of PRO-PMs to assess RFS. Methods: RAND Delphi methodology was employed to achieve conceptual consensus and measurement priorities. First, diverse cancer survivors were convened as a Delphi Panel. Themes from panelist brainstorming and related social media outreach, coupled with a detailed literature search, informed the Delphi survey development. Standard RAND Delphi survey methodology was followed, and panelists completed Survey 1. Areas of disagreement and uncertainty were the focus of discussion during a 2-day meeting, followed by Survey 2 completion /scoring. Results: The panel concluded that the term ‘return to functional status’ was inadequate. Structured discussion led to outcome re-naming as redefining functional status following a cancer diagnosis/completion of treatment. The Delphi method revealed priority measurement areas for survivors who have completed cancer treatment, and those receiving long term treatment. Priority areas include: overall quality of life; overall physical health; general mental health; changes in cognitive function; emotional problems; depression; fatigue; pain; changing dietary needs; late effects/side effects of treatment; ability to process loss or grief; maintaining everyday activities; overall independence; sense of control; and resilience. Conclusions: NCCS is a novel organization to lead measure development. NCCS engaged a diverse panel and used an accessible, structured approach to enable cancer survivors themselves to play the leadership role. Next steps for the project include development of pre-testing specifications for the prioritized PRO-PMs. Subsequent efforts will seek measure testing and endorsement. Ultimately, this work will contribute pragmatic methods/learning for future patient-led measure development.